Most proteins have a tendency to form polymers, which are accompanied by slow polymer formation when they are produced, stored, transported, and injected into a patient. There are two reasons for whyRead More…
Monoclonal Antibodies Crucial to Fighting Emerging Infectious Diseases
Monoclonal antibodies (mAbs) — preparations of a specific type of antibody designed to bind to a single target — have shown promise in the fight against cancer and autoimmune diseases. They alsoRead More…
Roche Reports 5 Deaths After Dosing of Hemlibra
Model of Factor VIII. © 3d ribbon/surface model of the human factor VIII after PDB 3CDZ. Ref.: Ngo JC, Huang M, Roth DA, Furie BC, Furie B (April 2008). DOI:10.1016/j.str.2008.03.001. Roche’s USRead More…
New Model, New drugs, and A ‘Remarkable’ Response in Adrenal Cancer
“Two new studies use new models to identify genetic targets and test promising treatments for adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year afterRead More…
Cancer Drug R&D and Market Trends from 2006 to 2017
Great Achievements Have Been Made in Cancer Drug Listing In 2006-2017, a total of 89 oncology therapies (NTDs) were approved by the Center for Drug Evaluation and Research (CDER). The Biologics EvaluationRead More…
New Monoclonal Antibody Drug Approvals Hit Record Levels in 2017
After more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine from targets development to technologies improvement. From clinical research to commercialization strategies,Read More…
Prediction of the World’s Top 10 Best-selling Drugs in 2018
Evaluate Pharma, a well-known market research organization in the field of medicine, recently released the report “EP Vantage 2018 Preview”, in which it reviewed the new drug approval in 2017, and predictedRead More…
Latest Research Results on CAR-T Therapy Reveal a Possible Reason of CAR-T Neurotoxicity
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
What Is the ROI of Anti-cancer Drug R&D? The Latest Research Showed that an Investment of $ 648 Million Can Generate Revenue of $ 1,658 Million
A new study recently calculated the development costs of 10 new anti-tumor drugs over the 10-year period between 2006 and 2015, and found that the median development time for these 10Read More…
Collaboration to Evaluate Combination of Nivolumab + Brentuximab Vedotin in Phase III Trial in Relapsed Hodgkin Lymphoma Expanded
“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…